Phase 2B dose selection of BG00011 for the treatment of idiopathic pulmonary fibrosis (IPF)

M. Arefayene (CAMBRIDGE, United States of America), M. Mouded (CAMBRIDGE, United States of America), C. Stebbins (CAMBRIDGE, United States of America), G. Zhao (CAMBRIDGE, United States of America), G. Song (CAMBRIDGE, United States of America), R. Christmann (CAMBRIDGE, United States of America), S. Violette (CAMBRIDGE, United States of America), D. Gallagher (CAMBRIDGE, United States of America)

Source: International Congress 2018 – Regenerative and anti-fibrotic approaches
Session: Regenerative and anti-fibrotic approaches
Session type: Poster Discussion
Number: 596
Disease area: Interstitial lung diseases

Congress or journal article abstractSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Arefayene (CAMBRIDGE, United States of America), M. Mouded (CAMBRIDGE, United States of America), C. Stebbins (CAMBRIDGE, United States of America), G. Zhao (CAMBRIDGE, United States of America), G. Song (CAMBRIDGE, United States of America), R. Christmann (CAMBRIDGE, United States of America), S. Violette (CAMBRIDGE, United States of America), D. Gallagher (CAMBRIDGE, United States of America). Phase 2B dose selection of BG00011 for the treatment of idiopathic pulmonary fibrosis (IPF). 596

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: